Argentina has approved Russia's one-dose Sputnik Light as a standalone COVID-19 vaccine and a booster shot, Reuters news agency reported on Monday.
The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, citing Argentina's health ministry, said a study in Argentina showed Sputnik Light was an "effective universal booster" when combined with vaccines produced by AstraZeneca (LON:AZN), Moderna (Nadaq:MRNA), China's Sinopharm and CanSino Biologics Inc.
RDIF markets Sputnik V internationally.
Reportedly, Argentina was one of the first countries to widely use Russia's Sputnik V COVID-19 vaccine.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses